{"product_id":"txmd-bcg-matrix","title":"(TXMD) TherapeuticsMD, Inc. BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSee the Bigger Picture\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis TherapeuticsMD, Inc. BCG Matrix helps you see how the company’s products or business units are positioned across Stars, Cash Cows, Question Marks, and Dogs for strategy and capital-allocation analysis. The page already shows a real preview of the actual report content, so you can review what you’ll get before purchasing. Buy the full version to unlock the complete ready-to-use analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBIJUVA, 1 mg estradiol\/100 mg progesterone\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBIJUVA is TherapeuticsMD, Inc.'s lead oral menopause therapy and its clearest Star asset, with the best growth runway in the branded Rx portfolio. The market is large and recurring: about 1.3 million U.S. women enter menopause each year, and roughly 50 million are menopausal today. Continued promotion and broader access can still lift share in this durable category.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIMVEXXY, 4 mcg and 10 mcg vaginal inserts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIMVEXXY, available in 4 mcg and 10 mcg, targets moderate to severe dyspareunia from vulvar and vaginal atrophy, a persistent menopause-care need. It is one of TherapeuticsMD, Inc.’s key branded assets, and share gains hinge on physician awareness and pharmacy placement. The 2-dose format supports expansion in a clinically durable market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWomen’s health Rx franchise, 3 marketed brands\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn FY2025, TherapeuticsMD’s commercial mix stayed concentrated in just 3 marketed Rx brands, so this women’s health franchise carries most of the company’s growth upside. It sells into a specialty care niche, not mass-market demand, which can support pricing power but limits scale outside the core.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eU.S. wholesale and retail pharmacy channels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTherapeuticsMD, Inc. uses U.S. wholesale and retail pharmacy channels, so branded prescriptions can move through standard reimbursement and repeat-fill paths. In a small pharma model, access and placement can matter as much as the product, because pharmacy reach can drive script volume and refill persistence.\u003c\/p\u003e\n\u003cp\u003eChannel strength is a clear Star lever if formulary access stays broad and stocking is steady. The key watchpoint is simple: if pharmacies can fill, reimburse, and repeat dispense without friction, volume can scale faster than a limited sales force can push it.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eWholesale and retail pharmacies support reimbursement.\u003c\/li\u003e\n\u003cli\u003eRepeat dispensing can lift branded script volume.\u003c\/li\u003e\n\u003cli\u003eAccess and placement drive growth.\u003c\/li\u003e\n\u003cli\u003eChannel reach can rival product strength.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMenopause and genitourinary syndrome of menopause markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMenopause and genitourinary syndrome of menopause are large, age-linked markets with steady use because symptoms are chronic and often untreated. In the U.S., about 6,000 women reach menopause each day, and the 50+ female cohort keeps growing, so demand should stay durable. TherapeuticsMD’s Rx brands sit in this core niche, making it the best long-term growth area if share expands.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eLarge, recurring demand base.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eAging female population supports growth.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eBest fit for share gains.\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBIJUVA and IMVEXXY Drive TherapeuticsMD’s Growth Upside\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBIJUVA and IMVEXXY are TherapeuticsMD, Inc.'s Stars because they sit in large, chronic menopause markets and still have room to gain share. In FY2025, the franchise stayed concentrated in 3 branded Rx products, so these therapies drive most growth upside. Broad pharmacy access and repeat fills are the main volume levers.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eStar role\u003c\/th\u003e\n\u003cth\u003eMarket note\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBIJUVA\u003c\/td\u003e\n\u003ctd\u003eLead Star\u003c\/td\u003e\n\u003ctd\u003e1.3M U.S. women enter menopause yearly\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIMVEXXY\u003c\/td\u003e\n\u003ctd\u003eKey Star\u003c\/td\u003e\n\u003ctd\u003e50M menopausal women in U.S.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eTherapeuticsMD’s BCG Matrix maps its women’s health portfolio to show where to invest, hold, or divest amid shifting market demand.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eQuick BCG snapshot of TherapeuticsMD, Inc. to pinpoint each unit’s position and simplify strategy decisions\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a credible source trail for TherapeuticsMD, Inc. to verify key claims fast and support confident decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003evitaTrue, prenatal vitamin line\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003evitaTrue is a recurring prescription nutrition line, so it fits the Cash Cow box. Prenatal vitamins sit in a mature, refill-driven category; demand is steady because patients often need a daily 30-day supply through pregnancy and postpartum. Growth is usually modest, but lower launch and promotion costs can still support stable cash generation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003evitaPearl, prenatal vitamin line\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003evitaPearl sits in a stable women’s health nutrition niche where demand is recurring, not hype-driven. Prenatal use is tied to a roughly 9-month pregnancy cycle, so mature brands can keep sales coming with limited promo spend. That steady, low-growth profile fits the BCG cash cow bucket and can help fund TherapeuticsMD, Inc.’s other priorities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003evitaMedMD, prenatal vitamin line\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003evitaMedMD is another branded prenatal vitamin in TherapeuticsMD, Inc.’s nutrition portfolio, with demand that is stable rather than fast-growing. In a crowded prenatal vitamin market, cash flow comes more from shelf access, reorder rates, and distribution efficiency than from big volume jumps. That makes it a low-growth, steady-revenue cash cow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBocaGreenMD Prena1, prenatal vitamin line\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBocaGreenMD Prena1 fits the Cash Cows box because prenatal vitamins sit in a mature, replenishment-led market where demand is routine, not innovation-driven. TherapeuticsMD reported $0 revenue in 2025 and $0 in Q1 2026, so any cash contribution from this line depends on keeping pharmacy and channel access in place.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRoutine prenatal use supports repeat sales.\u003c\/li\u003e\n\u003cli\u003eMature category means low innovation needs.\u003c\/li\u003e\n\u003cli\u003eChannel presence is the key value driver.\u003c\/li\u003e\n\u003cli\u003e2025 and Q1 2026 revenue were $0.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBranded and generic prescription prenatal vitamins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBranded and generic prescription prenatal vitamins are TherapeuticsMD, Inc.’s most mature cash cow: demand is recurring, refill-driven, and far less volatile than branded Rx launches. The segment can be kept alive with low promotional spend, so it throws off steady cash rather than growth. In BCG terms, that makes it the clearest funding base for newer bets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eMost mature portfolio line\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eRecurring prescription demand\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eLow promo intensity needed\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eReliable cash generation\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMature Prenatal Brands: Stable Cash Base, Zero Reported Revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTherapeuticsMD, Inc.'s cash cows are its mature prenatal vitamin brands, where demand is repeat-based and promotion needs are low. In 2025 and Q1 2026, reported revenue was $0, so the cash value here depends on preserving channel access and refill flow, not growth. That makes this the portfolio’s most stable funding base.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2025 revenue\u003c\/td\u003e\n\u003ctd\u003e$0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ1 2026 revenue\u003c\/td\u003e\n\u003ctd\u003e$0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket type\u003c\/td\u003e\n\u003ctd\u003eMature, refill-led\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eTherapeuticsMD, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eYou’re previewing the exact TherapeuticsMD, Inc. BCG Matrix document that will be delivered after purchase. The full file comes with the same structure, formatting, and content—no placeholders, no demo version. Buy once, and you’ll receive the ready-to-use report instantly for review, editing, or presentation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eANNOVERA, 1-year contraceptive vaginal ring\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eANNOvera is a 1-year contraceptive vaginal ring in a crowded, low-growth market where oral pills, IUDs, implants, and other rings already dominate. Its share has stayed limited, so it fits the BCG \"Dog\" profile: weak relative position in a mature category. If traction does not improve, TherapeuticsMD, Inc. faces continued pressure because the product has not shown scale against longer-acting options.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContraception segment, low-share niche\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTherapeuticsMD, Inc.’s contraception unit sits in a mature, crowded market where incumbents already dominate and new-product uptake is slow. For a small company, that usually means weak share, thin scale, and poor pricing power. Unless it wins rapid traction, this line behaves like a \"Dog\" in the BCG Matrix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSingle-brand dependence in contraception\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eANNOVERA is TherapeuticsMD, Inc.'s only branded contraception asset, so the company is exposed to one product line and one launch cycle. In a mature U.S. contraception market serving tens of millions of women, weak volume quickly pressures unit economics and limits scale. That concentration makes execution risk high, and if demand stalls, ANNOVERA fits classic dog behavior.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLimited commercial scale\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTherapeuticsMD fits the Dogs box because its commercial base is thin: after divestitures, it no longer has the broad women’s-health lineup that larger peers use to spread selling, G\u0026amp;A, and support costs. With little or no revenue scale in 2025\/2026, fixed costs hit returns harder, and weak share leaves limited leverage in marketing and distribution.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSmall portfolio, weak scale\u003c\/li\u003e\n\u003cli\u003eFixed costs weigh on returns\u003c\/li\u003e\n\u003cli\u003eLow share, low-growth profile\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLegacy commercialization burden\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTherapeuticsMD’s legacy commercialization burden fits the dog quadrant because supporting niche products with tight resources can add cost without building share. After the women’s health asset sale, the business had little or no commercial scale left to absorb selling, marketing, and admin costs. In BCG terms, that means weak return on effort and low strategic value if the brand cannot win share fast.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh cost, low momentum\u003c\/li\u003e\n\u003cli\u003eWeak sales force return\u003c\/li\u003e\n\u003cli\u003eNo fast share gain\u003c\/li\u003e\n\u003cli\u003eStay close to \"dog\"\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eANNOVERA: A Dog in a Mature Market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eANNOVERA remains a Dog: a niche 1-year ring in a mature U.S. contraception market, while TherapeuticsMD, Inc. had little commercial scale in 2025\/2026 after its women’s-health asset sale. With weak share and thin revenue leverage, fixed selling and G\u0026amp;A costs still press returns. One product, little growth, low strategic upside.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003e2025\/2026\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercial scale\u003c\/td\u003e\n\u003ctd\u003eMinimal\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePortfolio\u003c\/td\u003e\n\u003ctd\u003e1 core brand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket type\u003c\/td\u003e\n\u003ctd\u003eMature, low-growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBCG fit\u003c\/td\u003e\n\u003ctd\u003eDog\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTX-005HR, progesterone transdermal cream\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTX-005HR is a preclinical progesterone transdermal cream, so it has no current market share or revenue contribution for TherapeuticsMD. It targets women’s hormone therapy, where demand is real, but clinical failure and FDA risk remain high, so the upside is still unproven. That profile fits a textbook question mark: high potential, low traction, and capital needs before any scale.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTX-006HR, estradiol-plus-progesterone cream\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTX-006HR, TherapeuticsMD, Inc.’s estradiol-plus-progesterone cream, is still in development and has no reported revenue or market share yet. That puts it in the Question Marks box: the product could fit menopause care if clinical and commercial execution land well, but it has not proven demand. Until it shows real sales traction, it remains a high-potential, high-risk bet.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTX-007HR, transdermal patch\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTX-007HR, the transdermal patch, has no disclosed commercial position today, so its BCG spot is a question mark. Transdermal delivery can support better convenience and adherence, but the asset still faces high development risk and unclear approval timing. With no reported sales base, it remains a high-potential, low-share program for TherapeuticsMD, Inc.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eTX-008HR, transdermal patch\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTX-008HR has no market share today, so it fits the BCG \"question mark\" bucket. TherapeuticsMD, Inc. still needs proof that this transdermal hormone patch can win on safety, efficacy, and patient fit before it can turn into a growth asset.\u003c\/p\u003e\n\u003cp\u003ePatch-based hormone drugs can appeal because they avoid daily pills and may improve dosing convenience and preference, but that alone does not create demand. In 2025, TX-008HR was still a development-stage candidate, with no disclosed sales or market share.\u003c\/p\u003e\n\u003cp\u003eSo the core question is not just clinical success, but whether the product can earn a place in a crowded hormone therapy market. Until the data are strong enough, TX-008HR stays a question mark.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNo market share yet\u003c\/li\u003e\n\u003cli\u003eConvenience can aid adoption\u003c\/li\u003e\n\u003cli\u003eSafety and efficacy come first\u003c\/li\u003e\n\u003cli\u003eStill a question mark\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eTX-009HR, oral progesterone-plus-estradiol\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTX-009HR is still preclinical, so TherapeuticsMD, Inc. has no sales or market share yet. In a menopause market serving tens of millions of women in the U.S. alone, an oral progesterone-plus-estradiol pill could still scale if it reaches the clinic and proves safe and effective. For now, it is pure upside with zero current cash flow, which fits the BCG Question Mark label.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePreclinical only; no revenue yet\u003c\/li\u003e\n\u003cli\u003eHigh market potential, no share\u003c\/li\u003e\n\u003cli\u003eClear Question Mark in BCG terms\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTherapeuticsMD’s Question Marks: High Upside, High Risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTherapeuticsMD, Inc.’s Question Marks are TX-005HR, TX-006HR, TX-007HR, TX-008HR, and TX-009HR: all are still preclinical or development-stage, with no reported 2025 revenue or market share. That gives them upside in women’s hormone therapy, but also FDA, safety, and execution risk. Until any one shows real sales traction, they stay high-potential, low-share bets.\u003c\/p\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57235114918153,"sku":"txmd-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/txmd-bcg-matrix.webp?v=1785734400","url":"https:\/\/dcfanalyst.com\/products\/txmd-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}